TXG

10X GENOMICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

121.89
+1.75
+1.46%
Closed 19:37 09/18 EDT
OPEN
121.93
PREV CLOSE
120.14
HIGH
122.43
LOW
118.39
VOLUME
3.17M
TURNOVER
--
52 WEEK HIGH
125.92
52 WEEK LOW
45.11
MARKET CAP
12.71B
P/E (TTM)
-152.6678
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10X Genomics (TXG) Investor Presentation - Slideshow
The following slide deck was published by 10x Genomics, Inc. in conjunction with this event.
Seekingalpha · 3d ago
10x Genomics Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
GlobeNewswire · 5d ago
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
Zacks · 5d ago
10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome
Chromium Single Cell Multiome ATAC + Gene Expression brings together two methods to profile biological systems at single cell resolutionPLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it has begun shipping its Chromium Single Cell Multiome ATAC + Gene
GlobeNewswire · 5d ago
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
Zacks · 6d ago
10x Genomics Announces Pricing of Upsized Public Offering
PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions
GlobeNewswire · 09/11 04:16
Morgan Stanley Initiates Coverage On 10x Genomics with Overweight Rating, Announces Price Target of $135
Morgan Stanley initiates coverage on 10x Genomics (NASDAQ:TXG) with a Overweight rating and announces Price Target of $135.
Benzinga · 09/09 10:02
10x Genomics Announces Launch of a Follow-On Public Offering
PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company pursuant to a registration statement
GlobeNewswire · 09/08 21:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TXG stock price target is 120.25 with a high estimate of 140.00 and a low estimate of 100.00.
EPS
Institutional Holdings
Institutions: 204
Institutional Holdings: 63.17M
% Owned: 60.59%
Shares Outstanding: 104.26M
TypeInstitutionsShares
Increased
47
14.92M
New
86
14.48M
Decreased
22
7.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.01%
Healthcare Equipment & Supplies
-0.40%
Key Executives
Chairman/Independent Director
John Stuelpnagel
President/Co-Founder/Chief Scientific Officer/Director
Benjamin Hindson
Chief Executive Officer/Co-Founder/Director
Serge Saxonov
Chief Financial Officer
Justin McAnear
Chief Compliance Officer
Brad Crutchfield
Chief Human Resource Officer
Jean Philibert
Chief Compliance Officer
Bradford Crutchfield
General Counsel
Eric Whitaker
Independent Director
Sridhar Kosaraju
Independent Director
Mathai Mammen
Independent Director
Kimberly Popovits
Independent Director
Bryan Roberts
Independent Director
Shehnaaz Suliman
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average TXG stock price target is 120.25 with a high estimate of 140.00 and a low estimate of 100.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TXG
10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell gene expression solution, cell immune profiling solution, cell copy number variation (CNV) solution, Cell assay for transposase accessible chromatin (ATAC) solution. The Company’s Chromium platform enables analysis of individual biological components, such as up to millions of single cells. Its Visium platform is designed to identify where biological components are located and how they are arranged with respect to each other. Its molecular assays are used with its Chromium platform, and with its planned Visium platform, to provide sensitive and robust biochemistries that convert minute amounts of biological analytes into detectable signals.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of 10X Genomics Inc stock information, including NASDAQ:TXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TXG stock methods without spending real money on the virtual paper trading platform.